In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
about
Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitisComparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacinDo we need an intravenous fluoroquinolone?Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.Pharmacokinetics of sparfloxacin in patients with renal impairment.In vitro activities of enoxacin, enrofloxacin, sparfloxacin, and ciprofloxacin against Escherichia coli strains isolated from diarrheic lambs and kids.Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.Comparative antianaerobic activity of BMS 284756Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.Current perspectives on glycopeptide resistance.Future directions in antimicrobial chemotherapy.Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents.Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.Comparative activities of eight quinolones against members of the Bacteroides fragilis group.Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteriaComparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocciAntianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parametersTrovafloxacin: a new fluoroquinolone.Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve.In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.Comparative in-vitro activity of fleroxacin against 480 nosocomial isolates.
P2860
Q28263381-F500A324-1F26-4582-9BA6-6063AF937EAFQ28378625-7F9762FB-0EB0-4812-AA4C-A1D56FD6FBD3Q33606570-B8937AFA-A1BE-4281-9D19-3B90BDCBBC50Q33697562-8C936D87-5803-434A-8E24-E3528E377023Q33751682-79F302E6-5F4C-4930-B25D-F99B36AD7019Q33752612-3FD1F36E-2970-4AE6-962B-54D8AEB88F8EQ33762012-D5B9485E-F692-4275-B825-6E9A9CC6859FQ33762067-16B2FCEA-DF4D-421D-B35A-E07EA2BCD23BQ33981466-CFDD7F97-B5E2-43B7-A17E-A28FED485C39Q35136059-11AA29BA-ED44-4061-A52E-361EAB0461DFQ35136236-20E6199B-C2D5-4E29-B87A-374EF5F33848Q35368590-11C18D26-8E24-40FE-B9B0-D9F550F3F77CQ35530705-2161C03E-ACBA-4AAB-894B-F308874E61DAQ35815229-0F0CC658-BE3C-4216-A7E9-32455191D508Q35821293-3F4C1E9B-D190-42AE-A739-472D0F8D1A59Q35821986-24E083FB-4077-40B6-83EF-8F286B006862Q35836848-735F05EF-DD4A-4E28-B01A-6FE514015BC9Q35862887-293126C3-3830-4A01-8F4F-F932A50BFC13Q36669525-882E98A1-A9F1-47EF-936A-6FABA81644A2Q37132593-493E6975-091D-4842-AA17-28129A8828D4Q37133347-D8D01741-8D6A-4F50-A3DF-BECDBF4CCBE5Q37879173-05266E0B-6B37-47AB-862E-69B1F84FE58BQ39784655-33E75FCC-77CF-4AA2-9920-990EB3AC6A6DQ39867096-3DDFE5AA-9A5D-4201-80FE-CDCB8B65FB4FQ41767493-CCC07BB9-013A-455F-A1E0-B4B29D1705BBQ54190770-12C3E163-CB64-41B0-888A-8A16C4E5587A
P2860
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
description
1991 nî lūn-bûn
@nan
1991 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@ast
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@en
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@nl
type
label
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@ast
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@en
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@nl
prefLabel
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@ast
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@en
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@nl
P2860
P356
P1476
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
@en
P2093
P2860
P304
P356
10.1128/AAC.35.5.955
P407
P577
1991-05-01T00:00:00Z